Moléculas clave en la progresión del Carcinoma Celular Renal de células claras : evaluación estadística de su posible uso como biomarcadores clínicos
Clear cell Renal Cell Carcinoma (ccRCC) represents 75-80% of all renal carcinomas.\nccRCC's diagnosis is usually late and patient evolution is uncertain. These facts emphasize the\nrequirement of useful diagnostic and prognosis biomarkers to optimize the chance of cure.\nAt molecular level, ccR...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Tesis doctoral acceptedVersion |
| Lenguaje: | Español |
| Publicado: |
Facultad de Farmacia y Bioquímica
2015
|
| Materias: | |
| Acceso en línea: | http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=posgraafa&cl=CL1&d=HWA_1157 http://repositoriouba.sisbi.uba.ar/gsdl/collect/posgraafa/index/assoc/HWA_1157.dir/1157.PDF |
| Aporte de: |
| Sumario: | Clear cell Renal Cell Carcinoma (ccRCC) represents 75-80% of all renal carcinomas.\nccRCC's diagnosis is usually late and patient evolution is uncertain. These facts emphasize the\nrequirement of useful diagnostic and prognosis biomarkers to optimize the chance of cure.\nAt molecular level, ccRCC is characterized for the deregulation of angiogenic and cell\nmetabolism pathways. Expression of the pH regulator anhydrase carbonic enzyme, CAIX, and the,\nglucose transport GLUT1, were evaluated in ccRCC tumors. High expression of membrane GLUT1\nwas associated with worse disease free survival (DFS) independently of stage and nuclear grade.\nLow expression of membrane CAIX was associated with the presence of metastases at diagnosis.\nCAIX, as well as FGF21 hepatokine serum concentration, were significantly elevated in\nccRCC patients when compared to healthy individuals. While high serum levels of FGF21 was\nassociated with worse DFS independently of stage and nuclear grade, high circulating levels of\nCAIX were associated with tumor size, stage and shorter overall survival independently of nuclear\ngrade.\nResults obtained in this work will allow a better understanding of ccRCC's molecular\npathways and will contribute to patient follow up. |
|---|